Specific Point-of-Care Testing of Coagulation in Patients Treated with Dabigatran

被引:7
作者
Haertig, Florian [1 ,2 ]
Birschmann, Ingvild [3 ]
Peter, Andreas [4 ,5 ,6 ]
Ebner, Matthias [1 ,2 ,7 ]
Spencer, Charlotte [1 ,2 ]
Gramlich, Michael [8 ]
Richter, Hardy [1 ,2 ]
Kuhn, Joachim [3 ]
Lehmann, Rainer [4 ,5 ,6 ]
Blumenstock, Gunnar [9 ]
Zuern, Christine S. [8 ,10 ,11 ]
Ziemann, Ulf [1 ,2 ]
Poli, Sven [1 ,2 ]
机构
[1] Eberhard Karls Univ Tubingen, Dept Neurol & Stroke, Tubingen, Germany
[2] Eberhard Karls Univ Tubingen, Hertie Inst Clin Brain Res, Tubingen, Germany
[3] Ruhr Univ, Heart & Diabet Ctr, Inst Lab & Transfus Med, Bad Oeynhausen, Germany
[4] German Ctr Diabet Res DZD, Neuherberg, Germany
[5] Univ Tubingen, Helmholtz Ctr Munich, Inst Diabet Res & Metab Dis, Tubingen, Germany
[6] Inst Clin Chem & Pathobiochem, Dept Diagnost Lab Med, Tubingen, Germany
[7] Charite, Dept Internal Med & Cardiol, Campus Virchow Hosp, Berlin, Germany
[8] Univ Hosp Tubingen, Dept Cardiol, Tubingen, Germany
[9] Univ Tubingen, Dept Clin Epidemiol & Appl Biometry, Tubingen, Germany
[10] Univ Basel, Univ Hosp Basel, Dept Cardiol, Basel, Switzerland
[11] Univ Basel, Univ Hosp Basel, Cardiovasc Res Inst Basel, Basel, Switzerland
关键词
dabigatran; point-of-care testing; ecarin clotting time; thrombolysis; anticoagulation; DIRECT ORAL ANTICOAGULANTS; THROMBIN;
D O I
10.1055/s-0040-1721775
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Purpose Accurate and rapid assessment of coagulation status is necessary to guide thrombolysis or reversal of anticoagulation in stroke patients, but commercially available point-of-care (POC) assays are not suited for coagulation testing in patients treated with direct oral anticoagulants (DOACs). We aimed to evaluate the direct thrombin monitoring (DTM) test card by Helena Laboratories (Texas, United States) for anti-IIa-specific POC coagulation testing, hypothesizing that its POC-ecarin clotting time (POC-ECT) accurately reflects dabigatran plasma concentrations. Methods A prospective single-center diagnostic study (ClinicalTrials.gov-identifier: NCT02825394) was inducted enrolling patients receiving a first dose of dabigatran and patients already on dabigatran treatment. Blood samples were collected before drug intake and 0.5, 1, 2, 8, and 12hours after intake. POC-ECT was performed using whole blood (WB), citrated blood (CB), and citrated plasma (CP). Dabigatran plasma concentrations were determined by mass spectrometry. Results In total, 240 blood samples from 40 patients contained 0 to 275ng/mL of dabigatran. POC-ECT with WB/CB/CP ranged from 20 to 186/184/316seconds. Pearson's correlation coefficient showed a strong correlation between dabigatran concentrations and POC-ECT with WB/CB/CP (R-2=0.78/0.90/0.92). Dabigatran concentrations >30 and >50ng/mL (thresholds for thrombolysis, surgery, and reversal therapy according to clinical guidelines) were detected by POC-ECT with WB/CB/CP (>36/35/45 and >43/45/59seconds) with 95/97/97 and 96/98/97% sensitivity, and 81/87/94 and 74/60/91% specificity. Conclusion This first study evaluating DOAC-specific POC coagulation testing revealed an excellent correlation of POC-ECT with actual dabigatran concentrations. Detecting clinically relevant dabigatran levels with high sensitivity/specificity, the DTM assay represents a suitable diagnostic tool in acute stroke, hemorrhage, and urgent surgery.
引用
收藏
页码:782 / 791
页数:10
相关论文
共 25 条
[1]  
Ahmed N, 2017, EUR STROKE J, V2, P95, DOI 10.1177/2396987317699144
[2]   Reversal of dabigatran by intraosseous or intravenous idarucizumab in a porcine polytrauma model [J].
Akman, N. ;
Braunschweig, T. ;
Honickel, M. ;
Schuett, K. ;
Schoechl, H. ;
Stoppe, C. ;
Rossaint, R. ;
Grottke, O. .
BRITISH JOURNAL OF ANAESTHESIA, 2018, 120 (05) :978-987
[3]   STARD 2015: updated reporting guidelines for all diagnostic accuracy studies [J].
Bossuyt, Patrick M. ;
Cohen, Jeremie F. ;
Gatsonis, Constantine A. ;
Korevaar, Daniel A. .
ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (04)
[4]   Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants [J].
Ebner, Matthias ;
Birschmann, Ingvild ;
Peter, Andreas ;
Spencer, Charlotte ;
Haertig, Florian ;
Kuhn, Joachim ;
Blumenstock, Gunnar ;
Zuern, Christine S. ;
Ziemann, Ulf ;
Poli, Sven .
CRITICAL CARE, 2017, 21
[5]   Point-of-Care Testing of Coagulation in Patients Treated With Non-Vitamin K Antagonist Oral Anticoagulants [J].
Ebner, Matthias ;
Peter, Andreas ;
Spencer, Charlotte ;
Haertig, Florian ;
Birschmann, Ingvild ;
Kuhn, Joachim ;
Wolf, Martin ;
Winter, Natalie ;
Russo, Francesca ;
Zuern, Christine S. ;
Blumenstock, Gunnar ;
Ziemann, Ulf ;
Poli, Sven .
STROKE, 2015, 46 (10) :2741-2747
[6]   Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests [J].
Eller, Thomas ;
Busse, Jessica ;
Dittrich, Marcus ;
Flieder, Tobias ;
Alban, Susanne ;
Knabbe, Cornelius ;
Birschmann, Ingvild .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2014, 52 (06) :835-844
[7]   THE MEANING AND USE OF THE AREA UNDER A RECEIVER OPERATING CHARACTERISTIC (ROC) CURVE [J].
HANLEY, JA ;
MCNEIL, BJ .
RADIOLOGY, 1982, 143 (01) :29-36
[8]   Detecting Anti-IIa and Anti-Xa Direct Oral Anticoagulant (DOAC) Agents in Urine using a DOAC Dipstick [J].
Harenberg, Job ;
Schreiner, Rupert ;
Hetjens, Svetlana ;
Weiss, Christel .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2019, 45 (03) :275-284
[9]   Point-of-care testing of coagulation in patients treated with edoxaban [J].
Hartig, Florian ;
Birschmann, Ingvild ;
Peter, Andreas ;
Horber, Sebastian ;
Ebner, Matthias ;
Sonnleitner, Matthias ;
Spencer, Charlotte ;
Bombach, Paula ;
Stefanou, Maria-Ioanna ;
Kuhn, Joachim ;
Mengel, Annerose ;
Ziemann, Ulf ;
Poli, Sven .
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2020, 50 (03) :632-639
[10]   Why Bland-Altman plots should use X, not (Y+X)/2 when X is a reference method [J].
Krouwer, Jan S. .
STATISTICS IN MEDICINE, 2008, 27 (05) :778-780